SAT-LB031 Empagliflozin as an Add-On Medication to Subjects Uncontrolled on DPP4 Inhibitors and Metformin: Real World Data Supporting the Use of Empagliflozin as a Rational Second Add-On in Indian Type 2 Diabetic Patients
Abstract
Abstract A huge burden of uncontrolled type 2 diabetes mellitus (T2D) prevails in the Indian settings with an estimated prevalence of patients with >7 % HbA1c at 63 %1 and glycaemic control tends to decline over time with monotherapy2. Newer guidelines supported the use of DPP4 inhibitors along with SGLT2 inhibitors as sequential therapy in patients with type 2 diabetes mellitus. This study evaluated the real-world clinical effectiveness of Empagliflozin as second add-on therapy in overweight subjects with inadequately controlled type 2 diabetes mellitus (T2DM). This single-centre study included overweight adult subjects with poorly controlled T2DM on optimal dose of metformin and DPP4 inhibitors, (N, 110) (mean glycated haemoglobin [HbA1c] (standard deviation [SD]), 7.65 [± 0.34] %; and BMI [SD], 28.39 [± 1.87] kg/m2) treated with Empagliflozin (25 mg) as add-on therapy. Follow-up improvements in outcomes were analysed using the paired t-test. Safety parameters were also evaluated. The mean age and weight at baseline were 42 ± 9.6 years and 81.23 ± 5.54 kgs respectively, with a male to female ratio of 1:1. An established cardiovascular disease was present in 18.2 % patients. At the 24-week follow-up, Empagliflozin as add-on therapy demonstrated a significant reduction (P< 0.0001) in HbA1c, body weight and BMI, with a mean reduction (MR [SD]) of 0.46 [0.44-0.48] %, 5.22 [4.92-5.51] kg, and 1.82 [1.72-1.92] kg/m2, respectively, in the overall population. Reduction in urine…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.